Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a buy rating in a research note issued to investors on Friday morning.

Several other equities analysts have also commented on AMPH. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Trading Up 2.3 %

Shares of AMPH opened at $50.84 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. Amphastar Pharmaceuticals has a one year low of $36.56 and a one year high of $65.92. The stock has a 50-day moving average price of $47.27 and a 200 day moving average price of $43.18. The company has a market capitalization of $2.49 billion, a P/E ratio of 17.59, a P/E/G ratio of 0.88 and a beta of 0.83.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.75 by $0.10. The business had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. Sell-side analysts forecast that Amphastar Pharmaceuticals will post 3.71 EPS for the current fiscal year.

Insider Activity

In related news, CFO William J. Peters sold 10,282 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $4,162,175.69. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Richard K. Prins sold 17,101 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares of the company’s stock, valued at $1,463,130.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO William J. Peters sold 10,282 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,162,175.69. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,383 shares of company stock valued at $1,524,123. Insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Amphastar Pharmaceuticals by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company’s stock worth $174,145,000 after purchasing an additional 48,203 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Amphastar Pharmaceuticals during the fourth quarter worth approximately $410,000. Bridge City Capital LLC grew its position in Amphastar Pharmaceuticals by 0.8% in the first quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after buying an additional 275 shares during the last quarter. Annex Advisory Services LLC increased its holdings in shares of Amphastar Pharmaceuticals by 6.6% in the first quarter. Annex Advisory Services LLC now owns 14,777 shares of the company’s stock valued at $649,000 after buying an additional 917 shares in the last quarter. Finally, Guidance Capital Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 12.6% during the first quarter. Guidance Capital Inc. now owns 8,417 shares of the company’s stock valued at $343,000 after purchasing an additional 941 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.